Following the NICE recommendation of Translarna Oppenheimer analyst, Christopher Marai, caught up with PTC Therapeutics (NASDAQ: PTCT) management. He views ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE